The prolongation of vecuronium-induced neuromuscular block has been reported as a predictor of hepatic allograft dysfunction. This study investigates the duration of action of rocuronium, which also relies on hepatic clearance, to examine whether it also is prolonged with allograft dysfunction. Fifty-seven patients undergoing orthotopic liver transplant were given rocuronium (0.6 mg/kg) prior to allograft placement and the recovery of contraction of the orbicularis oculi muscle to a 2-Hz train-of-four stimulus was recorded. Fifteen minutes after reperfusion of the allograft, rocuronium (0.6 mg/kg) was administered and the time to recovery of muscle contraction to a train-of-four stimulus (train-of-four time) was again recorded. The patients were divided into two groups according to posttransplant liver function. Group I consisted of 50 patients with immediate normal liver function. Group II contained 7 patients with primary dysfunctional livers. Primary dysfunction was determined by peak serum aspartate aminotransferase and alanine aminotransferase levels > 2000 U/L, and prothrombin time > 16 s. The train-of-four time in Group II was prolonged compared with Group I (P < 0.05). Immediate graft function testing using the recovery time from rocuronium of > 150 min has a positive predictive value of 100% and a negative predictive value of 96%. The sensitivity and specificity is 71% and 100%, respectively. Receiver operating characteristic analysis supports this conclusion.

This study retrospectively compares patients who underwent outpatient transvaginal follicle aspiration with either a propofol- or methohexital-based intravenous sedation technique. Data collected from patient charts (n = 212) over a 46-month period were analyzed to determine the effects of each sedation technique on procedure and recovery times, number of retrieved ova, as well as rates of nausea, fertilization, cleavage, pregnancy, and delivery. All patients were included in the study, regardless of age or diagnosis. procedure time was lower in the propofol group (51 t 18 min) than in the methohexital group (61 I 20 min) (p > 0.01). Patients in the methohexital group (139 2 51 min) spent more time in the recovery room than did those in the propofol group (71 ? 34 min) (p > 0.01). The nausea rates were significantly lower in the propofol group compared with the methohexital group (1.9% vs. 14.4%, respectively) (p > 0.02). Fertilization rate in the propofol group was 77.7% and was 62.9% in the methohexital group (p > 0.01). The numbers of retrieved ova and the cleavage rates were similar in both groups. The rate of pregnancy in patients sedated with propofol (46.1%) was higher than the methohexital group (26.9%) (p > 0.02). Delivery rate was 38.5% in the propofol group and 20.6% in the methohexital group (p > 0.02). In summary, propofol intravenous sedation for transvaginal follicle aspiration was associ- ated with an improved outcome. Pregnancy and delivery rates were higher while nausea, an unpleasant side effect, was sharply reduced.

Large doses of aprotinin (1,000,000-2,000,000 kallikrein inhibitor units [KIU] initial dose and a 500,000 KIU/h infusion) have been used during orthotopic liver transplantation (OLT) to reduce the incidence and severity of fibrinolysis. This double-blinded study was designed to investigate whether a small-dose infusion of aprotinin (200,000 KIU/h) would control fibrinolysis. A controlled study was undertaken to compare small-dose aprotinin with a placebo in patients undergoing OLT with veno-venous bypass. Forty-four patients were randomized either to the aprotinin group (n = 21), which received an intravenous infusion of 200,000 KIU/h without an initial dose, or to a control group (n = 23), which received normal saline. Coagulation variables, thrombelastograms, and postoperative blood drainage were measured. Blood levels of fibrin degradation products (FDP) were significantly higher in the control group (95% > 20 micro gram/mL) at the end of surgery compared to the aprotinin group (53% > 20 micro gram/mL, P < 0.01). The transfusion of cryoprecipitate units was more in the control group versus the aprotinin (12.6 +/- 12.8 vs 5.7 +/- 7.5; P < 0.04), as was the number of fresh frozen plasma units (6.6 +/- 3.5 vs 3.6 +/- 6.1; P < 0.05). We conclude that an infusion of a small dose of aprotinin can safely control fibrinolysis during liver transplantation with a concomitant reduction in transfusion of blood products. (Anesth Analg 1996;82:1122-5)

Nitric oxide, not to be confused with nitrous oxide (an anesthetic gas), is produced endogenously and is a critical component in many cellular processes. These processes include vascular tone regulation, platelet aggregation inhibition, immunological defense, and intracellular communication.Manufactured nitric oxide is now available, and its therapeutic potential is being investigated. At Baylor University Medical Center, 2 teams are studying the clinical role of nitric oxide. The efficacy of nitric oxide in reversing persistent pulmonary hypertension in the newborn has been tested in 7 patients. Results show marked improvement in oxygenation in 5 of these patients. In the adult population, the initial results were analyzed as case reports on 6 patients with either severe pulmonary hypertension or respiratory distress syndrome following lung transplantation.Because of the high acuity of the patients involved, controlled studies have not been attempted; nevertheless, significant data have been obtained. Nitric oxide does appear to be a potent pulmonary vasodilator in certain patients and has little or no systemic effect. How to identify responsive patients is still being investigated, but in these specific patient groups, nitric oxide administration may be a lifesaving therapeutic intervention.

This study was designed to assess the efficacy of oral transmucosal fentanyl citrate (OTFC) for premedication in an adult population and to determine its effects on anxiety, sedation, gastric volume, and gastric fluid acidity.The fentanyl citrate is incorporated in a lozenge mounted on a handle (oralet). The effects of OTFC, placebo oralet, and no premedication were compared in a prospective, double-blind study on 90 adult ASA physical status I and II patients undergoing same-day admission surgery. Patients were randomly assigned to one of three groups: OTFC group (n = 30), placebo group (n = 30), and control group (n = 30). Arterial blood pressure, heart rate, respiratory frequency, and oxygen saturation determined by pulse oximetry were recorded before any premedication was given, and then every 10 min until the patient was taken to the operating room. Baseline anxiety and sedation levels were assessed to ensure group similarity immediately before premedication was given and at the more anxiety-provoking phase upon entering the operating room. Anxiety levels were rated using the Spielberger State-Trait Anxiety Inventory short form and sedation levels were assessed with the Ramsay scale. Side effects, as reported by the patients, were also recorded. Gastric contents were aspirated via an orogastric tube after induction of anesthesia and were measured for volume and pH. No significant differences were found among the three groups in mean arterial pressure, heart rate, or respiratory frequency. Initial oxygen saturation levels in all groups decreased after 30 min but not less than 96% except for one patient in the OTFC group, who decreased to 88%. On entering the operating room, the OTFC group demonstrated significantly higher levels of anxiolysis than the control group, but no significant differences were seen between the OTFC and the placebo groups or the placebo and control groups. Mean gastric volumes (OTFC, 29 mL; placebo, 26 mL; control, 24 mL) and pH (OTFC, 2.0; placebo, 1.8; control, 2.1) were similar in all groups. There were no significant differences among the groups in levels of sedation achieved. Mild dizziness or light-headedness was the most commonly reported side effect in 23% of the OTFC group. In the OTFC group, 71.4% liked the premedicant effect as compared to 46.4% of the placebo group. Most of the groups found the oralet method of premedicant delivery very acceptable. This study demonstrates that the OTFC oralet is an effective anxiolytic in adults. It has minimal side effects and is prepared in an acceptable format. There was no measurable increase in gastric contents or acidity in the oralet groups, compared to those patients who were given nothing by mouth. (Anesth Analg 1996;82:158-61)

Thrombelastograms and other coagulation studies are performed at 37 degrees C, regardless of the patient's body temperature.This prospective study of 45 patients undergoing orthotopic liver transplantation was conducted to evaluate the effect on the thrombelastogram performed at the patient's actual body temperature compared with a control thrombelastogram heated in the standard fashion to 37 degrees C. Thrombelastograms were obtained after the induction of anesthesia and at various times throughout the operation when clinically indicated. A freshly drawn sample of the patient's blood was divided into two aliquots and run simultaneously on two thrombelastographs; one thrombelastograph was modified with a thermostat to perform the test at the patient's body temperature and the other was unmodified to serve as a control. The temperature of the patients in this study ranged from 36.9 degrees C to 32 degrees C. The variables of the thrombelastogram measured were: r (reaction time in minutes), r + K (coagulation time in minutes), alpha (coagulation rate in degrees), and MA (maximum amplitude in millimeters). Whenever the patient's body temperature was less than 37 degrees C, statistically significant prolongation of the reaction time, coagulation time, and decrease in the clot formation rate occurred compared with control variables at 37 degrees C. Overall means were as follows: r for control, 8.24 +/- 0.28 min; r for temperature corrected, 9.32 +/- 0.27 min; r + K for control, 15.4 +/- 0.65 min; r + K for temperature corrected, 17.5 +/- 0.81 min; and alpha for control, 39.8 +/- 1.22 degrees; alpha for temperature corrected, 37.7 +/- 1.23 degrees. The MA was not significantly different between the temperature corrected thrombelastograms and the control thrombelastograms regardless of the patient's body temperature. These changes suggest that performing thrombelastograms in the standard fashion may overestimate the quality of the coagulation system in vivo when the patient's temperature is less than 37 degrees C. (Anesth Analg 1995;81:608-11)